Pharmacokinetic Study of Aprepitant in BEP Treatment of Patients With Testis Carcinoma (A-BEP)
Status:
Withdrawn
Trial end date:
2008-09-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to investigate whether there is an interaction occurs between
etoposide and aprepitant in patients with testis carcinoma treated with the standard BEP
regimen.
Also to determine how long treatment with aprepitant is necessary in BEP regimen for 5
consecutive days.